ClinicalTrials.gg
CompletedNCT04478708Updated Dec 10, 2025Results posted

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

A Phase 1 interventional study of maridebart cafraglutide and Placebo in Obesity, sponsored by Amgen. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Enrollment
22nd of 28
110 · median 275
Started
2020
the only one that year
Phase 1
14 of 28
3 open now
Registered
1st of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 22nd largest by enrollment, is the only one that started in 2020, is one of 14 in phase 1, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided before initiation of any study-specific activities/procedures.
  • Age ≥ 18 years to ≤ 65 years, at the time of signing the informed consent.
  • Except for obesity, otherwise healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and ECGs on day -2 (cohorts 1-6, cohort 11-13) or day -1 (cohorts 7-10) and screening.
  • between ≥ 30.0 kg/m\^2 and ≤ 40.0 kg/m\^2.
  • Have a stable body weight (\< 5 kg self-reported change during the previous 8 weeks) before screening.
  • Willing to maintain current general diet and physical activity regimen, except for the physical activity in the 72 hours before each blood sample collection for the clinical laboratory analysis, which should not be strenuous.
  • Females must be of nonreproductive potential

    • as defined as:
  • Age of ≥ 55 years with no menses for at least 12 months; OR
  • Age \< 55 years with no menses for at least 12 months AND with a follicle-stimulating hormone level > 40 IU/L or according to the definition of "postmenopausal range" for the laboratory involved; OR

    • History of hysterectomy; OR
    • History of bilateral oophorectomy.
  • For patients in cohorts 7-10 only, participants must have a smartphone device with the capability of downloading apps or other digital tools required for this cohort.

Exclusion criteria

Exclusion Criteria:

  • History or clinical evidence of diabetes mellitus, including (HbA1c) > 6.5% and/or a fasting glucose ≥ 125 mg/dl (6.9 mmol/L) at screening.
  • Triglycerides ≥ 5.65 mmol/L (ie, 500 mg/dL) at screening.
  • Screening calcitonin ≥ 50 ng/L.
  • Hepatic liver enzymes (AST), alanine aminotransferase (ALT), alkaline phosphatase, or total levels > 1.5 times the (ULN) at screening. If ALT is > 1.5 x the ULN at screening AND the AST, alkaline phosphatase, and total bilirubin levels are within normal limits, then participant may be eligible for enrollment after a discussion with the medical monitor.
  • History or clinical evidence of bleeding diathesis or any coagulation disorder, including (PT), activated partial thromboplastin time (PTT), international normalized ratio (INR), or count outside of the laboratory's normal reference range at screening. If a single value (PT, PTT, INR, or platelet count) is outside the normal reference range at screening and the participant does not have evidence of any other bleeding or coagulation disorder, then the participant may be eligible for enrollment after a discussion with the medical monitor.
  • History of gastrointestinal abnormality that could affect gastrointestinal motility (including small bowel or colonic resection, inflammatory bowel disease, irritable bowel disease, and colon or gastrointestinal tract cancer).
  • Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
  • Participants with a history of confirmed chronic pancreatitis or idiopathic acute pancreatitis.
  • Participants with a history of gall bladder disease (ie, cholelithiasis or cholecystitis) not treated with cholecystectomy.
  • Untreated or uncontrolled hypothyroidism/hyperthyroidism defined as thyroid stimulating hormone > 6 mIU/L or \<0.4 mIU/L.
  • A interval (QTc) at screening of > 450 msec in males or > 470 msec in females or history of long QT syndrome.
  • Participants with a history of renal impairment or renal disease and/or estimated ≤ 60 mL/min/1.73 m\^2.
  • Obesity induced by other endocrinologic disorders (eg, Cushing's Syndrome).
  • Previous surgical treatment for obesity (excluding liposuction if performed >1 year before study entry) and/or participants with recent (within 6 months) or planned endoscopic treatment for obesity.
  • History of major depressive disorder.
  • History of other severe psychiatric disorders, eg schizophrenia, bipolar disorder.
  • Any lifetime history of a suicidal attempt or of any suicidal behavior.
  • Surgery scheduled for the study duration period, except for minor surgical procedures, at the discretion of the investigator.
  • Positive results for antibodies, surface antigen, hepatitis B core antibody, or virus RNA. For hepatitis C, hepatitis C antibody testing is done at screening, followed by hepatitis C virus RNA by polymerase chain reaction if hepatitis C antibody is positive.
  • Systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg at screening, or on day -2. For each visit, if the initial blood pressure is elevated, the reading may be repeated once at least 15 minutes later and the lower of the 2 readings may be used.
  • History of of any type, other than in situ cervical cancer or surgically excised nonmelanomatous skin cancers occurring more than 5 years before randomization.
  • Use of the following agents are excluded unless there is a prior consultation between the investigator and Amgen medical monitor:

    • Prescription and nonprescription drugs within 14 days or 5 half-lives, whichever is longer, before the first dose of product, with exception of hormone replacement therapy (eg, estrogen, thyroid).
    • All herbal medicines, vitamins, and supplements within 30 days before receiving the first dose of investigational product.
    • Exceptions must be reviewed and approved by the investigator and Amgen medical monitor. Written documentation of this review and Amgen acknowledgment is required for participant participation.
  • Current or history of treatment with medications that may cause significant weight gain or loss, within 3 months before screening, including systemic (except for a short course of treatment, ie, 7 to 10 days), tricyclic antidepressants, atypical antipsychotic and mood stabilizers (eg, imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium).
  • Current participation (or within the last 3 months) in an organized weight reduction program or currently using or used within 3 months before screening: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phentermine, naltrexone, bupropion, lorcaserin, metformin, or any GLP-1R agonists (either by prescription or as part of a clinical study).
  • Prior exposure to maridebart cafraglutide or AMG 598 or currently receiving treatment in another investigational device or drug study, or less than 5 half-lives since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
  • Female participants with a positive pregnancy test assessed at screening and/or day -2 by a serum pregnancy test and/or urine pregnancy test) or female participants who are breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 5 months after the last dose of maridebart cafraglutide.
  • Male participants with a female partner of who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use an acceptable method of during treatment and for an additional 5 months after the last dose of maridebart cafraglutide.
  • Male participants unwilling to abstain from donating sperm during treatment and for an additional 5 months after the last dose of maridebart cafraglutide.
  • Participant has known sensitivity to maridebart cafraglutide or components thereof or a history of drug or other allergy that is in the opinion of the investigator or medical monitor (if appropriate), contraindicates their participation.
  • Participant has a known sensitivity to GLP-1R agonists.
  • Participant has known sensitivity to mammalian derived products.
  • Participant has an allergy or known sensitivity to acetaminophen.
  • Participant is unwilling or unable to limit alcohol consumption throughout the course of the study. Alcohol is prohibited 48 hours before day -2 and is limited to no more than to 2 drinks per day for males and 1 drink per day for females for the duration of the study (1 drink being equivalent to 12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of wine, or 1.5 ounces of 80 proof distilled spirits).
  • Participant uses nicotine or tobacco containing products (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, e-cigarettes, pipes, or nicotine patches) within 6 months before screening. Participant is unwilling or unable to abstain from nicotine or tobacco, cigars, cigarettes, pipes, or nicotine patches throughout the course of the study.
  • Participant is tested positive for alcohol and/or drugs of abuse at screening.
  • History of substance abuse (ie, alcohol, licit or illicit drugs) within 12 months before screening.
  • Participant is unwilling to refrain from strenuous exercise (eg, heavy lifting, weight training, and aerobics) for 72 hours before each blood collection for clinical laboratory tests.
  • Participant has donated or lost ≥ 500 mL of blood or plasma within 60 days of day -2.
  • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.
  • History or evidence of any other disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion.
  • For participants in cohorts 7-10 and cohorts 12-13 only, the Patient Health Questionnaire-9 (PHQ-9) score of ≥ 10 up to day 1.
  • For participants in cohorts 7-10 and 12-13 only, any suicidal ideation as identified by endorsement of (answered yes to) any of the items numbered 1-5 on the Columbia Suicide Severity Rating Scale (C-SSRS) up to day 1.
  • For participants in cohorts 7-10 and 12-13 only, participant has systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 95 mm Hg on day 1. For each visit, if the initial blood pressure is elevated, the reading may be repeated once at least 15 minutes later and the lower of the 2 readings may be used.
  • For participants in cohorts 7-10 and 12-13 only, a QTc of > 450 msec in males or > 470 msec in females up to day 1.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Part A: maridebart cafraglutide

    Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).

    Biological: maridebart cafraglutide

  • Placebo comparator
    Part A: Placebo

    Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).

    Drug: Placebo

  • Experimental
    Part B: maridebart cafraglutide

    Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).

    Biological: maridebart cafraglutide

  • Placebo comparator
    Part B: Placebo

    Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).

    Drug: Placebo

  • Experimental
    Part C: maridebart cafraglutide

    Up to 2 open-label, multiple ascending dose cohorts (cohorts 12 to 13) treated with doses previously studied in Part A and Part B.

    Biological: maridebart cafraglutide

Interventions

  • Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.

  • DrugPlacebo

    Participants will receive placebo as a single dose in Part A and multiple doses in Part B.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event (AE) which started on or after the first dose of AMG 133. Clinically significant changes in laboratory safety tests, vital signs and 12-lead electrocardiograms (ECGs) were included as AEs.

    Time frame: Part A: 150 days; Part B: 207 days; Part C Cohort 12: 193 days; Part C Cohort 13: 207 days

Secondary outcomes

  1. Part A: Maximum Observed Concentration (Cmax) of AMG 133

    The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.

    Time frame: Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150

  2. Part B: Cmax of AMG 133

    The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported.

    Time frame: Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 61, 63, 71, 78, 85, 127, 169 and 207. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 63, 71, 78, 85, 169 and 207

  3. Part A: Time of Maximum Observed Concentration (Tmax) of AMG 133

    The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.

    Time frame: Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150

  4. Part B: Tmax of AMG 133

    The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported.

    Time frame: Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 61, 63, 71, 78, 85, 127, 169 and 207. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 63, 71, 78, 85, 169 and 207

  5. Part A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of AMG 133

    The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.

    Time frame: Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150

  6. Part B: AUC From Day 0 to 28 (AUC0-28) of AMG 133

    The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported. This parameter shows the AUC over the 28-day dosing interval, both from Day 1 to Day 29 (predose) and from Day 57 to Day 85.

    Time frame: Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 57 (predose), 61, 63, 71, 78 and 85. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 57 (predose), 63, 71, 78 and 85

  7. Percentage of Participants With Anti-AMG 133 Antibody Formation

    The percentage of participants who developed anti-AMG 133 antibodies (binding and if positive, neutralizing to native GLP-1, when available) at any time was presented.

    Time frame: Part A Cohort 1-6 and 11: Up to Day 150. Part B Cohort 7-10 and Part C Cohort 13: Up to Day 207. Part C Cohort 12: Up to Day 193

07

Results

Posted Dec 10, 2025

Participant flow

A total of 110 participants were enrolled into this trial in the United States between August 2020 and November 2022.

Participant flow — Overall Study
MilestonePart A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD SC Placebo (Cohorts 1-5, 11)Part A SAD IV Placebo (Cohort 6)Part B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133Part B MAD Cohorts 7-9 PlaceboPart B MAD Cohort 10 PlaceboPart A SAD Cohort 11 AMG 133Part C MAD Cohort 12Part C MAD Cohort 13
Started6676661226681063668
Completed655655112553553564
Not completed01201110115510104
Withdrew: Lost to follow-up00000000111210000
Withdrew: Withdrawal of consent from study01201110004300104

Outcome measures

SecondaryPart A: Maximum Observed Concentration (Cmax) of AMG 133

The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.

Time frame:
Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150
Reported as:
Geometric mean · µg/mL
Part A: Maximum Observed Concentration (Cmax) of AMG 133
µg/mLPart A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD Cohort 11 AMG 133
Intact AMG 1331.31 ± 0.5593.42 ± 1.186.09 ± 2.8015.7 ± 11.435.8 ± 10.322.7 ± 4.1041.5 ± 7.35
Total AMG 1331.43 ± 0.6143.68 ± 1.166.78 ± 3.1617.1 ± 11.837.7 ± 12.522.9 ± 4.2143.2 ± 7.07
SecondaryPart B: Cmax of AMG 133

The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported.

Time frame:
Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 61, 63, 71, 78, 85, 127, 169 and 207. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 63, 71, 78, 85, 169 and 207
Reported as:
Geometric mean · µg/mL
Part B: Cmax of AMG 133
µg/mLPart B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133
Intact AMG 133 after dosing on Day 18.30 ± 2.5914.5 ± 5.9927.4 ± 12.417.8 ± 5.32
Total AMG 133 after dosing on Day 18.75 ± 2.5616.2 ± 6.5230.1 ± 12.318.8 ± 5.15
Intact AMG 133 after dosing on Day 5710.4 ± 2.1921.9 ± 6.4765.1 ± 20.427.2 ± 5.20
Total AMG 133 after dosing on Day 5713.1 ± 2.8627.1 ± 8.1280.8 ± 23.233.2 ± 6.77
SecondaryPart A: Time of Maximum Observed Concentration (Tmax) of AMG 133

The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.

Time frame:
Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150
Reported as:
Median · days
Part A: Time of Maximum Observed Concentration (Tmax) of AMG 133
daysPart A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD Cohort 11 AMG 133
Intact AMG 1335.0 (2.9 to 6.9)4.9 (3.9 to 6.9)6.0 (5.0 to 13)5.8 (2.8 to 13)3.9 (2.9 to 6.9)0.025 (0.0049 to 0.044)5.4 (1.9 to 6.0)
Total AMG 1335.9 (4.0 to 6.9)4.9 (3.9 to 14)7.0 (6.0 to 13)6.9 (3.8 to 21)4.4 (2.9 to 6.9)0.043 (0.0049 to 0.044)5.9 (1.9 to 6.0)
SecondaryPart B: Tmax of AMG 133

The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported.

Time frame:
Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 61, 63, 71, 78, 85, 127, 169 and 207. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 36, 43, 50, 57 (predose), 63, 71, 78, 85, 169 and 207
Reported as:
Median · days
Part B: Tmax of AMG 133
daysPart B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133
Intact AMG 133 after dosing on Day 15.9 (3.8 to 6.2)6.0 (4.1 to 14)5.9 (3.9 to 15)4.0 (3.8 to 7.0)
Total AMG 133 after dosing on Day 16.0 (3.8 to 6.2)6.0 (4.1 to 14)5.9 (3.9 to 15)4.0 (3.8 to 14)
Intact AMG 133 after dosing on Day 574.7 (4.1 to 15)4.3 (3.7 to 6.0)4.1 (4.0 to 5.1)6.0 (6.0 to 6.0)
Total AMG 133 after dosing on Day 575.6 (4.1 to 7.2)6.2 (3.7 to 14)4.1 (4.0 to 5.1)6.0 (6.0 to 6.0)
SecondaryPart A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of AMG 133

The pharmacokinetic parameter estimates of intact and total AMG 133 after a single administration of AMG 133 were reported.

Time frame:
Cohort 1-5, 11: Day 1 predose and 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 7, 8, 15, 22, 29, 43, 57, 71, 92, 120 and 150. Cohort 6: Day 1 predose and 10 mins, 1, 2, 4 and 8 hours postdose, Day 2, 3, 4, 5, 6, 15, 22, 29, 43, 57, 71, 92, 120 and 150
Reported as:
Geometric mean · mcg*day/mL
Part A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of AMG 133
mcg*day/mLPart A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD Cohort 11 AMG 133
Intact AMG 13339.0 ± 13.6108 ± 35.2230 ± 56.2442 ± 263762 ± 196205 ± 67.91150 ± 280
Total AMG 13356.4 ± 20.3151 ± 51.2300 ± 104629 ± 3751100 ± 321264 ± 1121720 ± 468
SecondaryPart B: AUC From Day 0 to 28 (AUC0-28) of AMG 133

The pharmacokinetic parameter estimates of intact and total AMG 133 after multiple administrations of AMG 133 were reported. This parameter shows the AUC over the 28-day dosing interval, both from Day 1 to Day 29 (predose) and from Day 57 to Day 85.

Time frame:
Cohorts 7-9: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 57 (predose), 61, 63, 71, 78 and 85. Cohort 10: Day 1 (predose), Day 5, 7, 15, 22, 29 (predose), 57 (predose), 63, 71, 78 and 85
Reported as:
Geometric mean · mcg*day/mL
Part B: AUC From Day 0 to 28 (AUC0-28) of AMG 133
mcg*day/mLPart B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133
Intact AMG 133 after dosing on Day 1 up to Day 29149 ± 23.5246 ± 95.5594 ± 201347 ± 28.7
Total AMG 133 after dosing on Day 1 up to Day 29181 ± 26.0300 ± 122697 ± 244419 ± 43.7
Intact AMG 133 after dosing on Day 57 up to Day 85214 ± 18.7443 ± 1361220 ± 432512 ± 79.7
Total AMG 133 after dosing on Day 57 up to Day 85297 ± 27.7599 ± 2241610 ± 624691 ± 114
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event (AE) which started on or after the first dose of AMG 133. Clinically significant changes in laboratory safety tests, vital signs and 12-lead electrocardiograms (ECGs) were included as AEs.

Time frame:
Part A: 150 days; Part B: 207 days; Part C Cohort 12: 193 days; Part C Cohort 13: 207 days
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
participantsPart A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD SC Placebo (Cohorts 1-5, 11)Part A SAD IV Placebo (Cohort 6)Part B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133Part B MAD Cohorts 7-9 PlaceboPart B MAD Cohort 10 PlaceboPart A SAD Cohort 11 AMG 133Part C MAD Cohort 12Part C MAD Cohort 13
Number of Participants With Treatment-emergent Adverse Events (TEAEs)02565631668830656
SecondaryPercentage of Participants With Anti-AMG 133 Antibody Formation

The percentage of participants who developed anti-AMG 133 antibodies (binding and if positive, neutralizing to native GLP-1, when available) at any time was presented.

Time frame:
Part A Cohort 1-6 and 11: Up to Day 150. Part B Cohort 7-10 and Part C Cohort 13: Up to Day 207. Part C Cohort 12: Up to Day 193
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-AMG 133 Antibody Formation
percentage of participantsPart A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133Part A SAD Cohort 11 AMG 133Part C MAD Cohort 12Part C MAD Cohort 13
Binding antibody positive16.750.028.633.316.716.70.033.325.030.033.316.712.5
Neutralizing antibody positive0.00.00.016.70.00.00.00.00.00.016.70.00.0

Adverse events

Collected over All-cause mortality and serious adverse events, from enrollment to end of study; median duration (min, max) in months: 4.93 (0.13, 7.03). TEAEs from first dose of study drug until end of study; duration with median (min, max) in months: 4.93 (0.13, 7.03). TEAE time frame for Part A: 150 days; Part B: 207 days; Part C Cohort 12: 193 days; Part C Cohort 13: 207 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A SAD Cohort 1 AMG 1330/6 (0%)0/6 (0%)0/6 (0%)
Part A SAD Cohort 2 AMG 1330/6 (0%)0/6 (0%)2/6 (33.3%)
Part A SAD Cohort 3 AMG 1330/7 (0%)0/7 (0%)5/7 (71.4%)
Part A SAD Cohort 4 AMG 1330/6 (0%)0/6 (0%)6/6 (100%)
Part A SAD Cohort 5 AMG 1330/6 (0%)0/6 (0%)5/6 (83.3%)
Part A SAD Cohort 6 AMG 1330/6 (0%)0/6 (0%)6/6 (100%)
Part A SAD SC Placebo (Cohorts 1-5, 11)0/12 (0%)0/12 (0%)3/12 (25%)
Part A SAD IV Placebo (Cohort 6)0/2 (0%)0/2 (0%)1/2 (50%)
Part B MAD Cohort 7 AMG 1330/6 (0%)0/6 (0%)6/6 (100%)
Part B MAD Cohort 8 AMG 1330/6 (0%)0/6 (0%)6/6 (100%)
Part B MAD Cohort 9 AMG 1330/8 (0%)0/8 (0%)8/8 (100%)
Part B MAD Cohort 10 AMG 1330/10 (0%)0/10 (0%)8/10 (80%)
Part B MAD Cohorts 7-9 Placebo0/6 (0%)0/6 (0%)3/6 (50%)
Part B MAD Cohort 10 Placebo0/3 (0%)0/3 (0%)0/3 (0%)
Part A SAD Cohort 11 AMG 1330/6 (0%)0/6 (0%)6/6 (100%)
Part C MAD Cohort 120/6 (0%)0/6 (0%)5/6 (83.3%)
Part C MAD Cohort 130/8 (0%)0/8 (0%)6/8 (75%)
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPart A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD SC Placebo (Cohorts 1-5, 11)Part A SAD IV Placebo (Cohort 6)Part B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133Part B MAD Cohorts 7-9 PlaceboPart B MAD Cohort 10 PlaceboPart A SAD Cohort 11 AMG 133Part C MAD Cohort 12Part C MAD Cohort 13
NauseaGastrointestinal disorders0/62/64/74/65/66/63/120/25/64/68/83/101/60/35/64/66/8
ConstipationGastrointestinal disorders0/60/60/71/60/63/61/120/22/61/60/80/100/60/33/65/64/8
VomitingGastrointestinal disorders0/61/64/75/65/62/60/120/24/65/66/87/100/60/34/62/62/8
DyspepsiaGastrointestinal disorders0/61/64/70/60/63/61/120/21/60/61/80/100/60/30/60/60/8
DiarrhoeaGastrointestinal disorders0/60/60/70/60/60/62/120/21/60/62/82/100/60/30/63/61/8
ChillsGeneral disorders0/60/60/70/60/60/60/120/20/60/64/80/100/60/30/60/60/8
HeadacheNervous system disorders0/61/63/71/60/62/61/121/21/62/61/83/103/60/31/61/63/8
Early satietyGeneral disorders0/60/60/70/60/62/60/120/20/60/60/80/100/60/30/60/60/8
Decreased appetiteMetabolism and nutrition disorders0/60/61/70/60/62/60/120/21/60/60/80/100/60/31/61/60/8
Taste disorderNervous system disorders0/60/60/70/60/60/60/120/20/60/60/80/100/60/30/62/60/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD SC Placebo (Cohorts 1-5, 11)Part A SAD IV Placebo (Cohort 6)Part B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133Part B MAD Cohorts 7-9 PlaceboPart B MAD Cohort 10 PlaceboPart A SAD Cohort 11 AMG 133Part C MAD Cohort 12Part C MAD Cohort 13Total
<=18 years000000000000000000
Between 18 and 65 years5676661226681063668109
>=65 years100000000000000001
Sex: Female, Male
Sex: Female, Male(Participants)Part A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD SC Placebo (Cohorts 1-5, 11)Part A SAD IV Placebo (Cohort 6)Part B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133Part B MAD Cohorts 7-9 PlaceboPart B MAD Cohort 10 PlaceboPart A SAD Cohort 11 AMG 133Part C MAD Cohort 12Part C MAD Cohort 13Total
Female5132124012754115347
Male1544548254152251563
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD SC Placebo (Cohorts 1-5, 11)Part A SAD IV Placebo (Cohort 6)Part B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133Part B MAD Cohorts 7-9 PlaceboPart B MAD Cohort 10 PlaceboPart A SAD Cohort 11 AMG 133Part C MAD Cohort 12Part C MAD Cohort 13Total
Hispanic or Latino12110052244102351245
Not Hispanic or Latino5465667042404015665
Unknown or Not Reported000000000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A SAD Cohort 1 AMG 133Part A SAD Cohort 2 AMG 133Part A SAD Cohort 3 AMG 133Part A SAD Cohort 4 AMG 133Part A SAD Cohort 5 AMG 133Part A SAD Cohort 6 AMG 133Part A SAD SC Placebo (Cohorts 1-5, 11)Part A SAD IV Placebo (Cohort 6)Part B MAD Cohort 7 AMG 133Part B MAD Cohort 8 AMG 133Part B MAD Cohort 9 AMG 133Part B MAD Cohort 10 AMG 133Part B MAD Cohorts 7-9 PlaceboPart B MAD Cohort 10 PlaceboPart A SAD Cohort 11 AMG 133Part C MAD Cohort 12Part C MAD Cohort 13Total
American Indian or Alaska Native000010000000000001
Asian000000001000001024
Native Hawaiian or Other Pacific Islander000000000000000000
Black or African American2253054031101004233
White44235182257105352472
More than one race000000000000000000
Unknown or Not Reported000000000000000000
08

Study locations

3 sites
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
09

References and documents

Publications

  • Veniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, Wu B, Falsey JR, Hager T, Thomas VA, Ambhaikar M, Sharpsten L, Zhu Y, Kurra V, Jeswani R, Oberoi RK, Parnes JR, Honarpour N, Neutel J, Strande JL. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6(2):290-303. doi: 10.1038/s42255-023-00966-w. Epub 2024 Feb 5. PubMed 38316982 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Nov 2022, 27 months.

Results were first posted in Dec 2025, 3 years after primary completion.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 27 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2020
First posted
Jul 21, 2020
StartActual
Aug 7, 2020
Primary completionActual
Nov 18, 2022
CompletionActual
Nov 18, 2022
Results first posted
Dec 10, 2025
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04478708
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Aug 7, 2020
Primary completion
Nov 18, 2022
Completion
Nov 18, 2022
Results posted
Dec 10, 2025
Last update
Dec 10, 2025

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion